Open Access Peer-reviewed Review

Current trends in targeted therapy of leukaemia and lymphoma

Main Article Content

Mariastefania Antica corresponding author
Josipa Skelin


Decades of cancer and leukaemia research have provided priceless insight into the molecular mechanisms underlying the development and maintenance of malignancies. The ultimate goal of these findings was, and still is, discovering discriminating factors enabling detection or treatment of tumour cells. An important achievement in this field has been the integration of protein chemistry, fluorescence detectors, nanoparticles, optical devices and computational devolvement integrated in the field of flow cytometry, fluorescence activated cell sorting FACS, data analysis and visualisation. Especially important is the onset of computational data mining tools like T-distributed Stochastic Neighbor Embedding (t- SNE), developed by van der Maatenand Hinton and further continuous progress of the machine learning algorithms for visualization of the huge amount of data produced from single cell FACS or mass cytometry analysis.

targeted therapy, leukaemia, lymphoma

Article Details

How to Cite
Antica, M., & Skelin, J. (2019). Current trends in targeted therapy of leukaemia and lymphoma. Advances in General Practice of Medicine, 2(1), 16-18.


  1. van der Maaten LJP and Hinton GE. Visualizing Data Using t-SNE. Journal of Machine Learning Research, 2008, 9: 2579-2605.
  2. Miliotou AN and Papadopoulou LC. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Current Pharmaceutical Biotechnology, 2018, 19(1): 5-18.
  3. Mclaughlin P, Grillo-L´opez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 1998, 16(8): 2825-2833.
  4. Zhang and Bodi. Ofatumumab. mAbs, 2009, 1(4): 326-331.
  5. Owen C and Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opinion on Biological Therapy, 2012, 12(3): 343-351.
  6. Grillo-L´opez and Antonio J . Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Review of Anticancer Therapy, 2002, 2(5): 485-493.
  7. Kantarjian HM, Deangelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. The New England journal of medicine, 2016, 375(8): 740-753.
  8. Baron J and Wang ES. Gemtuzumab ozogamicin for the treatment of acutemyeloid leukemia. Expert Review of Clinical Pharmacology, 2018, 11: 549-559.
  9. Schweighofer CD andWendtner CM. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Oncotargets & Therapy, 2010, 3: 53-67.
  10. Ansell SM. Brentuximab vedotin. Blood, 2014, 124(22): 3197-3200.
  11. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature, 2015, 526: 525-530.
  12. Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica, 2013, 98(12): 1930-1938.
  13. Mojtaba A, Kum-Ja L, Ashley W, et al. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Therapeutics and Clinical Risk Management, 2016, 12: 1301-1310.
  14. Sanders S and Stewart DA. Targeting non-Hodgkin Lymphoma with Blinatumomab. Expert Opinion on Biological Therapy, 2017, 17: 1013-1017.
  15. Berenstein R. Class III Receptor Tyrosine Kinases in Acute LeukemiaBiological Functions and Modern Laboratory Analysis. Biomarker insights, 2015, 10: BMI-S22433..
  16. Drake JM, Lee JK and Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Molecular & Cellular Biology, 2014, 34(10): 1722-1732.
  17. Ohanian M, Cortes J, Kantarjian H, et al. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opinion on Pharmacotherapy, 2012, 13(7): 927-938.
  18. Man LM, Morris AL and Keng M. New Therapeutic Strategies in Acute Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2017, 12(3): 197-206.
  19. Ling Y, Xie Q, Zhang Z, et al. Protein kinase inhibitors for acute leukemia. Biomarker Research, 2018, 6(1): 8.
  20. Suraweera A, O’Byrne KJ and Richard DJ. Combination Therapy WithHistone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achievingthe Full Therapeutic Potential of HDACi. Frontiers in oncology, 2018, 8: 92.
  21. Guillamot M, Cimmino L and Aifantis I. The Impact of DNA Methylation in Hematopoietic Malignancies. Trends in Cancer, 2016, 2: 70-83.
  22. Fenaux P. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol, 2009, 10: 223-232.
  23. Kadia TM, Thomas XG, Dmoszynska A, et al. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. American Journal of Hematology, 2015, 90(7): E139-E141.
  24. Csizmar CM, Kim DH and Sachs Z. The role of the proteasome in AML. Blood Cancer Journal, 2016, 6(12): e503.
  25. Crawford LJ, Walker B and Irvine AE. Proteasome Inhibitors in Cancer Therapy. Journal of Cell Communication and Signaling, 2011, 5(2): 101-110.
  26. Park JE, Miller Z, Jun Y, et al. Next-generation proteasome inhibitors for cancer therapy. Translational Research, 2018: S1931524418300446.